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Abstract 
Purpose: To formulate avanafil, a recently approved phosphodiesterase-5 enzyme inhibitor, in 
liposomal form for enhanced transdermal permeation and bioavailability  
Methods: Two preparation procedures were employed, leading to the formation of multilamellar 
vesicles (MLVs) and reverse-phase evaporation unilamellar vesicles (ULVs). The effects of the 
preparation method and lipid content on the encapsulation efficiency and particle size were studied. 
Studies assessing the stability, in vitro release, ex vivo permeation and in vivo bioavailability were also 
conducted in rats.  
Results: The preparation of avanafil liposomes as MLVs, the addition of cholesterol, and the use of 
more rigid phospholipids all increased the avanafil encapsulation efficiency within the liposomes (95.61 
%). The stability studies revealed that the liposomes prepared using phospholipids with higher transition 
temperatures (dipalmitoyl-L-α-phospatidylcholine) were significantly more stable for a longer period of 
time after storage at 25 ± 0.5 ˚C and 60 ± 5 % relative humidity for a period of 2 months (p < 0.05). In 
vivo pharmacokinetic results from rats showed a significant increase in the bioavailability of avanafil 
from transdermal liposomal formulations of up to 7-fold (p < 0.05) compared to the topical drug 
suspension.  
Conclusion: The developed avanafil liposomes represent a promising transdermal drug delivery 
system for the treatment of erectile dysfunction. 
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Avanafil was recently approved by two 
international pharmaceutical regulating bodies, 
the United States Food and Drug Administration 
(USFDA) and the European Medicines Agency 
(EMA) [1]. Avanafil is a phosphodiesterase-5 
enzyme inhibitor and a second-generation 
erectile dysfunction medication [2,3]. Avanafil 
has advantages over other PDE5 inhibitors, as it 
is more selective for the PDE5 isoenzyme and a 
variety of cellular targets than sildenafil and 
tadalafil [4]. 
 
Avanafil is slightly soluble in ethanol, practically 
insoluble in water, and soluble in 0.1 mol/L 
hydrochloric acid, and it undergoes a first pass 
effect.  Therefore, the enhancement of its 
bioavailability is essential for the development of 
effective clinical formulations [4]. 
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The skin, due to its structure, is considered a 
complex organ for drug delivery. Although the 
stratum corneum is considered the most 
important barrier to drug absorption through the 
skin, in recent years, transdermal drug delivery 
has been used to overcome the problems 
associated with skin barrier properties [5,6]. The 
utilization of novel delivery systems, including 
vesicular drug delivery systems such as 
liposomes, has recently been proposed [7]. 
These novel systems exhibit superior 
pharmacological properties [8]. Their activity 
depends on various factors, including their 
rigidity, lipid membrane composition, and 
encapsulation efficiency [9]. The use of vesicular 
drug delivery systems has been studied for both 
oral and dermal applications [10]. 
 
Therefore, the aim of this research was to 
prepare avanafil in liposomes to enhance its 
transdermal permeability and bioavailability for 






Avanafil was purchased from Jinlan Pharm-
Drugs Technology Co., Ltd. [Hangzhou, China]. 
The egg phosphatidylcholine (PC), Lecithin, and 
cholesterol (CH) were purchased from Sigma 
Chemical Company (St Louis, USA). Dipalmitoyl-
L-α-phospatidylcholine (DPPC) was purchased 
from Fluka Chemical Company (Buchs, 
Switzerland). All other reagents were 
commercially available and of analytical grade. 
  
Preparation of multilamellar liposomal 
vesicles (MLVs)  
 
Avanafil MLVs were prepared using the lipid film 
hydration technique [11]. 50 mg of avanafil, and 
100 mg of lipid composed of phospholipid, 
lecithin, and cholesterol in different ratios, were 
solubilized in 10 ml mixture of chloroform and 
methanol (1:1 ratio) in a round-bottom flask. The 
organic solvent was evaporated at 33 °C on a 
rotary evaporator (Buchi R-110 Rotavapor, 
Switzerland). Liposomes were prepared by 
dispersing the lipid component film in an isotonic 
phosphate-buffered saline solution pH 7.4 (10 
ml). This procedure was carried out at 55 °C 
under mechanical stirring. The liposomal 
suspension was left to mature overnight at 4 °C 
to ensure full lipid hydration. Finally, the 
liposomal suspension was passed 5 times 
through a 4.5 µm microporous filter and 10 times 
through a 2.2 µm microporous filter for 
purification and kept in a refrigerator. 
Preparation of reverse-phase evaporation 
(REVs) liposomes  
 
Avanafil unilamellar vesicles (ULVs) were 
prepared using the reverse-phase evaporation 
technique [12]. 100 mg of the lipid component, 
composed of phospholipid, lecithin, and 
cholesterol in different ratios, were solubilized in 
a 10 ml mixture of chloroform and methanol (1:1 
v/v). A thin lipid film was formed and dissolved in 
10 ml ether and 10 ml acetone solution 
containing 50 mg avanafil and 10 ml phosphate 
buffer saline (PBS, pH 7.4). Sonication was 
continued for approximately 30 min until the 
organic solvent was evaporated. The liposomes 
were allowed to equilibrate at room temperature, 
and 10 ml PBS was added to the liposomal 
suspension and passed five times through a 4.5-
µm and 10 times through a 2.2-µm microporous 
filter for purification. Samples were stored in a 
refrigerator overnight. 
 
Determination of the avanafil encapsulation 
efficiency in liposomes  
 
The free drug component was removed from the 
liposomal suspension by centrifugation for 45 
min. at 15000 rpm (Beckman Coulter Inc, 
Fullerton, CA). The concentration of (AVA) in the 
supernatant was quantified by HPLC with an 
Agilent 1200 series equipped with a UV diode 
array detector. A reversed-phase column (25 cm 
× 4.6 mm (i.d.) C18, 5 µm – Intersil® ODS-3 (GL 
Sciences Inc, Japan)) was used. The column 
effluent was monitored with a UV detector at 230 
nm, and the eluent flow was determined to be 1.3 
ml/min. The mobile phase included acetonitrile 
and methanol in a 0.05 M ammonium acetate 
buffer, pH 2.5 (20:20:60 v/v/v). The AVA 
retention time was 5 min. The encapsulation 
efficiency (EE, %) was calculated as in Eq 1.  
 
EE (%) = {(1- AF)/AT}100 …………………….. (1) 
 
where AF and AT represent the free and total 
avanafil content, respectively. 
 
EE was used to evaluate the effect of the 
preparation method, lipid composition, and type 
of charge on the encapsulation of avanafil in 
liposomes. 
 
Size analysis of liposomes  
 
To test the droplet size and zeta potential of the 
avanafil liposomes, 100 μL of each liposomal 
suspension was diluted in 20 mL of distilled 
water. The mean droplet size and zeta potential 
of the resulting dispersion was determined by 
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dynamic light scattering using a Zetatrac 
machine from Microtrac Inc. (PA, USA). 
 
Studies on drug-leakage from vesicles  
 
The different liposomal formulations were sealed 
in 30-mL vials and stored at various 
temperatures (4-8 ˚C, 25 ± 0.5 ˚C and 60 ± 5 % 
relative humidity) for a period of two months. 
Samples from each formula at each temperature 
were withdrawn at defined time intervals. The 
stability was evaluated by comparing % EE for 
each liposomal suspension. 
 
In vitro drug release studies 
 
In vitro release profiles of avanafil liposomals and 
aqueous dispersions were performed in an open-
ended cylindrical tube with one end tied with a 
dialysis membrane. Each sample being tested 
was placed in an open-ended cylinder and 
suspended in 250 ml of phosphate buffer 
receptor medium (pH 7.4) in a beaker placed on 
a thermostat magnetic stirrer and constantly 
stirred at 50 rpm and 37 ± 1 °C. Sample aliquots 
(5 ml) were withdrawn from the receptor 
compartment at predetermined time intervals of 
5, 15, 30, 60, 120, 180, and 240 min. After the 
collection of each sample, the same volume of 
fresh medium was added. The avanafil content in 
the withdrawn samples was estimated by HPLC, 
as described earlier. 
 
Ex vivo skin permeation studies  
 
Full thickness skin samples (3 × 3 cm) were 
excised from the abdominal region of shaved 
male Wistar rats. The samples were freed from 
any subcutaneous fat and examined using a 
magnifier to assure skin integrity. The prepared 
skin was mounted between the donor and 
receptor compartments of the diffusion cells, with 
the dermal side in direct contact with the receptor 
medium. The amounts of permeated avanafil 
from the F7 formula and the pure drug were 
determined using HPLC.  
 
Skin-retention studies  
 
After conducting the ex vivo permeation study, 
the skin pieces mounted on the diffusion cells 
were removed. The remaining formulation 
adhering to the skin samples was scraped off, 
and the skin pieces were wiped with tissue 
paper. Each cleaned skin piece was cut and 
shaken in methanolic solution for 24 h to ensure 
complete drug extraction. The filtrate was 





Bioavailability analysis was conducted in rats in 
an attempt to explore the capability of the 
transdermal liposomal formulations in improving 
avanafil’s pharmacokinetic parameters. Male 
Sprague Dawley rats weighing ~300 g were used 
for the experiments. The rats were fasted for 12 
hours prior to administering the drug formulation. 
The rats were given free access to water.  
 
All experimental protocols were conducted after 
being approved by the Animal Ethics Committee 
of King Abdulaziz University, Jeddah KSA, 
ensuring that the care and use of all animals 
conformed to the European Union (EU) Directive.   
The animals were divided into two groups (n = 
6): the avanafil liposomal suspension group 
(group I), and the avanafil aqueous suspension 
group (group II). After trimming the back hair in 
one square spot, the F7 formula and the 
aqueous avanafil suspension were applied 
transdermally at a dose equivalent to 10 mg/kg. 
At predetermined time intervals, blood samples 
of 0.2 ml were withdrawn using a heparinized 
tube by retro-orbital puncture. Blood samples 
were then centrifuged at 10,000 g for 8 min to 
separate the plasma. The samples were then 
stored in sterile polypropylene vials at -20 °C. 
The resulting plasma drug concentrations were 




Differences among the group means were 
analysed for statistical significance using one-
way ANOVA followed by the Tukey-Kramer 
Multiple Comparisons Test. Differences were 
considered significant at p < 0.05. Statistical 
analysis was performed using SPSS for 




Encapsulation efficiency (EE) 
 
Table 1 shows that the EE had higher values for 
the MLVs than for the ULVs of the same 
composition and molar ratio. Furthermore, EE 
had higher values for the DPPC-containing 
liposomes than for the egg phosphatidylcholine 
(PC)-containing liposomes of same molar ratio. 
Concerning the effects of the cholesterol content 
on the EE% of avanafil in liposomes, the results 
showed that the EE% can be increased by 
increasing the cholesterol (CH) content to a 
certain limit, above which the EE% decreases 
when the (CH) concentration increases. 
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Table 1: Particle size and encapsulation efficiency of avanafil multilamellar and unilamellar liposomes 
 
Batch 










































































Note: PC = phosphatidylcholine; CH = cholesterol; DPPC, dipalmitoyl-L-α-phospatidylcholine.; Lec = Lecithin; 
MLVs = multilamellar vesicles; ULVs = unilamellar vesicles. Data represent mean ± SD (n = 3) 
 
The above results clearly show that liposomes 
prepared as MLVs with a lipid composition of 
DPPC:Lecithin:CH in a molar ratio  of 3:1:3 had a 
higher EE % [95.61 ± 2.31] than all other 
liposome formulations. 
 
Size profile of liposomes 
 
Table 1 shows the particle sizes of the 
liposomes. The mean particle diameter of the 




The results indicate that the liposomal 
formulation prepared with egg 
phosphatidylcholine (PC) was withdrawn from 
the study after one month because storage at 25 
°C led to a substantial loss (75 %) of avanafil. In 
the case of the liposomal formulation prepared 
with dipalmitoyl-L-α-phospatidylcholine (DPPC), 
the drug leakage from vesicles was less than 5 
% at the end of test period, indicating the stability 
of these formulations (Table 2). 
 
Ex Vivo Permeation 
 
Figure 1 shows the transdermal permeation 
profile of avanafil in the 1 % drug suspension and 
formula F7. The drug permeation levels after 12 
h for the liposomal suspension and pure drug 
suspension were significantly different (p < 0.05). 
The cumulative amount of avanafil permeated 
from liposomal dispersion after 12 h was 2615 ± 
127 µg (52.30 %), while the cumulative amount 
permeated from the avanafil suspension was 
only 613 ± 41 (12.36 %). 
 
 
Figure 1: Cumulative rat skin permeation of avanafil 




Table 2: Effect of storage at 25 ± 0.5˚C and 60 ± 5% RH (relative humidity) for a period of 2 months on the mean 














0 0.722 72.15±1.56 0.864 95.61±2.31 
15 1.212 44.27±1.31 0.881 93.23±2.28 
30 2.754 18.37±0.95 0.912 92.11±2.05 
45 - - 0.931 91.50±1.97 
60 - - 0.952 90.97±1.89 
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The results of the skin retention study indicate 
that the % of avanafil retained within the skin in 
case of formula F7 was higher than that from the 





The plasma concentration–time profiles for 
avanafil after the transdermal administration of 
liposomal formulation and aqueous suspension 
are shown in Figure 2. The pharmacokinetic 
parameters for all groups were calculated using 
Kinetica software (Kinetica 5.0.11, Thermo 
Fisher Scientific Inc, Waltham, MA USA) (Table 
3). The AUC of the liposomal formulation was 
found to be 127.45 ng/ml.hr, which was 
significantly (p < 0.05) greater than that of the 
drug suspension (17.23 ng/ml.hr). When the 
Cmax values were compared, a significant 
increase was observed in the liposomal 





The results revealed that the avanafil 
encapsulation efficiency in the different prepared 
liposomal formulations varied depending on the 
method of preparation and the lipid composition 
used in the prepared liposomes. The method of 
liposome preparation also had an effect on the 
encapsulation efficiency of avanafil. EE had 
higher values in MLVs than in ULVs of the same 
composition and molar ratio. This may be 
because the liposomes were prepared at a pH of 
7.4, and avanafil has pH-dependent solubility, 
with minimum solubility in basic medium. This, a 
higher pH should increase the unionized fraction 
of the drug, which is lipophilic in nature. Because 
the MLVs contained multiple lamellae capable of 
loading a higher mass of lipophilic drug than the 
ULVs [13], EE had higher values in the MLVs 
than in the ULVs of the same composition and 
molar ratio. 
 
Concerning the effect of the type of 
phospholipids on EE, the results showed that the 
EE% had higher values in the DPPC-containing 
liposomes than the egg PC-containing liposomes 
of the same molar ratio. This result may be 
because the encapsulation of avanafil depends 
on the fluidity of the phospholipid bilayer; the 
lower the fluidity, the greater the EE%. DPPC is 
a synthetic product with a higher phase transition 
temperature (42.5 ± 0.25 °C) than egg PC (-7 °C) 
[14], so the fluidity of DPPC is less than that of 
egg PC. 
 
Table 3: Pharmacokinetic parameters of avanafil after the transdermal administration of 10 mg/kg of formula F7 
and 10 mg/kg of avanafil aqueous suspension. The significance level was set at p < 0.05 
 
AUC0-∞ (ng.h/ml) MRT 
 (hr) 
AUC0-t 
(ng.h/ml) Cmax (ng/ml) Tmax (h) 
Formulation 
















Figure 2: Plasma-concentration time curve of avanafil after the transdermal application of a 10 mg/kg dose of 
Batch F7 (ӿ) or a 10 mg/kg dose of the aqueous avanafil suspension (○); p < 0.05 
Hosny & Aldawsari 
Trop J Pharm Res, April 2015; 14(4):   
 
564 
This could lead to the increased EE % in the 
liposomes containing DPPC. Concerning the 
effect of the cholesterol content on the EE % of 
avanafil in liposomes, our results showed that the 
EE% could be increased by increasing the (CH) 
content to a certain limit. However, above that 
limit, the EE% actually decreased with further 
increases in the (CH) concentration. This is 
because cholesterol increases the rigidity of the 
bilayer. A more rigid bilayer results in a higher 
stability and reduces the permeability of the 
liposomal membrane [15], increasing the drug 
retention [16]. After a certain concentration, 
cholesterol can disrupt the regular linear 
structure of the liposomal membrane [17]. 
 
The mean particle diameter of the MLVs was 
larger than that of the ULVs. This was due to the 
presence of several phospholipid bilayers in MLV 
liposomes, leading to an increase in their mean 
particle size. These results can be attributed to 
the higher EE% of the MLVs, which increases 
the spacing between adjacent layers, resulting in 
the formation of larger liposomes than in the 
ULVs [18].  
 
The better stability of the DPPC liposomes 
compared with the PC liposomes may be 
attributed to the high phase-transition 
temperature of DPPC [42.5 oC] relative to the low 
phase-transition temperature of PC (–7 oC). 
Thus, the fluidity of DPPC is less than egg PC, 
leading to a decrease in drug leakage in 
liposomes prepared with DPPC. 
 
The results of the ex vivo permeation studies 
indicated that the liposomal suspensions showed 
a 4-fold higher permeation % than aqueous 
suspension. This may be explained by the fact 
that liposomes can adsorb to the skin surface 
and transfer membrane-associated drug directly 
to the cell membrane, thereby facilitating drug 
passage across the skin [19]. Another possible 
reason is the lower solubility of avanafil at pH 
7.4; at this pH, avanafil is present in its unionized 
form, producing a cloudy solution [20]. In this 
form, avanafil is insoluble, leading to decreased 
permeation. In order for drug permeation to 
occur, the drug must first be present in the 
soluble form, either in aqueous or lipid solution. 
This leads to a decrease in the % permeated 
from the aqueous avanafil suspension compared 
to the avanafil liposomal suspension, in which 
the drug remained solubilized in either the 
aqueous phase or the lipid bilayers of the 
liposomes. 
 
The results of skin retention test could be 
attributed to the high retention of the drug in 
vesicular systems due to its intrinsic liposome–
skin interaction behaviour. These results were in 
accordance with several research studies 
showing that liposome-associated drugs can be 
better routed into the skin [21-23]. The poor 
retention of the aqueous drug dispersion may be 
due to the presence of drug in an insoluble form, 
which acts as a barrier for its penetration and 
retention within skin layers. 
 
The enhanced bioavailability of the liposomal 
formulations after transdermal administration is 
likely due to a combination of the following 
factors. First, liposomal vesicles provide a 
delivery vector by which avanafil can cross the 
skin barrier. Second, liposomal vesicles can 
introduce avanafil as a fine dispersion, unlike the 
coarse particles delivered in a standard drug 
suspension, with a correspondingly increased 
surface area and a reduced diffusion path length. 
Third, a higher adhesion surface contact 
between the liposomal vesicles and absorption 
site was afforded. When the MRT of the 
prepared liposomal formulation was compared 
with that of aqueous suspension, the liposomal 
was found to be higher than that of the aqueous 
suspension. This result could be ascribed to the 
retention of liposomes within the skin layers for a 
longer period of time, allowing them to serve as a 
drug reservoir for extended release into the 
viable epidermis over several hours. The relative 
bioavailability of the liposomal formulation was 
739.6 with respect to the drug suspension. Thus, 
there was a 7.3-fold increase in the avanafil 





Suitable liposomal transdermal delivery systems 
of avanafil for potential use in the treatment of 
erectile dysfunction have been developed. The 
use of multilamellar vesicles and the 
incorporation of cholesterol and more rigid 
phospholipids both increase the encapsulation 
efficiency of the drug within the liposomes. The 
bioavailability of avanafil in its transdermal 
liposomal formulation was 7.3-fold compared to 
the topical drug suspension. The developed 
formulation is therefore a promising transdermal 
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